Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
ACTIVE_NOT_RECRUITING
Status
Conditions
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Transitional Cell Carcinoma
- Fallopian Tube Undifferentiated Carcinoma
- Ovarian Clear Cell Adenocarcinoma
- Ovarian Endometrioid Tumor
- Ovarian Seromucinous Carcinoma
- Ovarian Serous Tumor
- Ovarian Transitional Cell Carcinoma
- Ovarian Undifferentiated Carcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Ovarian Endometrioid Adenocarcinoma
- Recurrent Primary Peritoneal Carcinoma
Interventions
- PROCEDURE: Biospecimen Collection
- DRUG: Carboplatin
- DRUG: Cediranib Maleate
- PROCEDURE: Computed Tomography
- PROCEDURE: Echocardiography Test
- DRUG: Gemcitabine
- DRUG: Gemcitabine Hydrochloride
- OTHER: Laboratory Biomarker Analysis
- PROCEDURE: Magnetic Resonance Imaging
- PROCEDURE: Multigated Acquisition Scan
- DRUG: Olaparib
- DRUG: Paclitaxel
- DRUG: Pegylated Liposomal Doxorubicin Hydrochloride
- OTHER: Pharmacological Study
- OTHER: Quality-of-Life Assessment
Sponsor
National Cancer Institute (NCI)
Collaborators
- [object Object]
- [object Object]